CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Methylene blue has only recently been noted to cause severe central nervous system toxicity. Methylene blue is used for various conditions, including, intravenously, in methemoglobinemia, vasoplegia and as an aid to parathyroidectomy (at doses of 1–7.5 mg kg−1). This review of the current evidence concludes that 13 of 14 of the reported cases of CNS toxicity were serotonin toxicity that met the Hunter Serotonin Toxicity Criteria. That has important preventative and treatment implications. Serotonin toxicity is precipitated by the monoamine oxidase inhibitor (MAOI) property of methylene blue interacting with serotonin reuptake inhibitors. Serotonin toxicity is reviewed, using the lessons inherent in the methylene blue story and experience, to illustrate how the mechanisms and potency of serotonergic drugs interact to determine severity. Recent human data showed that an intravenous dose of only 0.75 mg kg−1 of methylene blue produced a peak plasma concentration of 500 ng ml−1(1.6 µM), indicating that the concentration in the central nervous system reaches a level that inhibits monoamine oxidase A. That is consonant with the actual occurrence of severe serotonin toxicity in humans at the dose of only 1 mg kg−1. It seems that all proposed uses of methylene blue entail levels that block monoamine oxidase, so cessation of serotonin reuptake inhibitors should be very carefully considered before using methylene blue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821 · cited 2×
“Good descriptions of the pathophysiology (Isbister and Buckley, 2005), clinical presentation (Boyer and Shannon, 2005), management and treatment (Gillman, 1999; Isbister et al.”
BackgroundDunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,029
Monoamine transporters and psychostimulant drugs
Rothman, R. B., & Baumann, M. H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.054 · Cited by 502 · cited 1×
“SRIs attenuate the effect of releasers by blocking their uptake into the pre-synaptic neuron, so there is no potential for ST with that combination (Mechan et al., 2002; Rothman and Baumann, 2003).”
BackgroundMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman, P. K. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei210 · Cited by 397 · cited 4×
“…diagnosis of NMS may be made because prior ingestion of an anti-psychotic is thought to ‘trump’ a diagnosis of ST: prior administration of anti-psychotics is not a reason to suspend a diagnosis of ST, if serotonergic drugs have been ingested and characteristic symptoms are present (Gillman, 2005b).”
BackgroundSelf-citationThe serotonin syndrome and its treatment
Gillman, P. K. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300111 · Cited by 306 · cited 1×
“Good descriptions of the pathophysiology (Isbister and Buckley, 2005), clinical presentation (Boyer and Shannon, 2005), management and treatment (Gillman, 1999; Isbister et al., 2007; Sun-Edelstein et al., 2008) are available.”
BackgroundSelf-citationRamsay, R. R., Dunford, C., & Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707430 · Cited by 276 · cited 3×
“…the data unequivocally demonstrating that MB is a potent selective reversible inhibitor of monoamine oxidase A (MAO-A) at nanomolar concentrations (Ramsay et al., 2007), confirming several older publications suggesting MB’s antidepressant activity and ability to raise serotonin (Aeschlimann et…”
BackgroundMethodSelf-citationMethylene blue and Alzheimer's disease
Oz, M., Lorke, D. E., & Petroianu, G. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.034 · Cited by 257 · cited 4×
“The pharmacology of MB is discussed in more detail by Stanford et al. (2009) and Oz et al. (2009).”
BackgroundInfluentialA Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 248 · cited 14×
“…spectrum concept of ST, which highlights that it is a synaptic 5-HT concentration related phenomenon; this spectrum concept has been elaborated, combining animal and human data, to show the extent to which various classes of drugs, and their various combinations, elevate serotonin (Gillman, 2006a).”
BackgroundMethodResultInfluentialSelf-citationSerotonin toxicity: a practical approach to diagnosis and treatment
Isbister, G. K., Buckley, N. A., & Whyte, I. M. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01282.x · Cited by 230 · cited 5×
“Good descriptions of the pathophysiology (Isbister and Buckley, 2005), clinical presentation (Boyer and Shannon, 2005), management and treatment (Gillman, 1999; Isbister et al., 2007; Sun-Edelstein et al., 2008) are available.”
BackgroundMethodInfluentialWhyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg062 · Cited by 228 · cited 1×
“This has been confirmed by analysis of large prospective case series of thousands of overdoses (Whyte, 2004; Whyte et al., 2003) and the side-effects encountered in trials, and case reports (Gillman, 2006a).”
ResultMechan, A. O., Esteban, B., O'Shea, E., Elliott, J. M., Colado, M. I., & Green, A. R. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704442 · Cited by 221 · cited 1×
“SRIs attenuate the effect of releasers by blocking their uptake into the pre-synaptic neuron, so there is no potential for ST with that combination (Mechan et al., 2002; Rothman and Baumann, 2003).”
BackgroundIsbister, G. K., & Buckley, N. A. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000177642.89888.85 · Cited by 199 · cited 4×
“, 2003; Whyte and Dawson, 2002) and also in the definition of the toxidrome of ST in both animals and humans (Dunkley et al., 2003; Isbister and Buckley, 2005; Whyte, 2004).”
BackgroundInfluentialDrug-induced serotonin syndrome: a review
Sun-Edelstein, C., Tepper, S. J., & Shapiro, R. E. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.5.587 · Cited by 168 · cited 1×
“Good descriptions of the pathophysiology (Isbister and Buckley, 2005), clinical presentation (Boyer and Shannon, 2005), management and treatment (Gillman, 1999; Isbister et al., 2007; Sun-Edelstein et al., 2008) are available.”
BackgroundSerotonin syndrome: history and risk
Gillman, P. (1998) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00976.x · Cited by 167 · cited 2×
“…in the quantification of the frequency and severity of ST risk with different classes of drugs when taken in therapeutic doses or overdose (Gillman, 1998, 2005a, 2006a,b; Isbister et al., 2003; Whyte and Dawson, 2002) and also in the definition of the toxidrome of ST in both animals and…”
BackgroundSelf-citationEndogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo
Wegener, G., Volke, V., & Rosenberg, R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703349 · Cited by 167 · cited 2×
“…potent selective reversible inhibitor of monoamine oxidase A (MAO-A) at nanomolar concentrations (Ramsay et al., 2007), confirming several older publications suggesting MB’s antidepressant activity and ability to raise serotonin (Aeschlimann et al., 1996; Naylor et al., 1987; Wegener et al., 2000).”
BackgroundMeissner, P. E., Mandi, G., Coulibaly, B., Witte, S., Tapsoba, T. L., Mansmann, U., Rengelshausen, J., Schiek, W., Jahn, A., Walter‐Sack, I., et al. (2006) · Malaria Journal · doi:10.1186/1475-2875-5-84 · Cited by 131 · cited 2×
“gov) in: for example, malaria (Meissner et al., 2006; Zoungrana et al., 2008), bipolar disorder and dementia (Wischik et al.”
BackgroundMethodWischik, C. M., Bentham, P., Wischik, D. J., & Seng, K. M. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.05.438 · Cited by 118 · cited 1×
“MB is undergoing something of a renaissance and is currently being used for various conditions in 13 registered trials (see ClincalTrials.gov) in: for example, malaria (Meissner et al., 2006; Zoungrana et al., 2008), bipolar disorder and dementia (Wischik et al., 2008).”
Zoungrana, A., Coulibaly, B., Sié, A., Walter‐Sack, I., Mockenhaupt, F. P., Kouyaté, B. A., Schirmer, R. H., Klose, C., Mansmann, U., Meissner, P. E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001630 · Cited by 102 · cited 2×
“gov) in: for example, malaria (Meissner et al., 2006; Zoungrana et al., 2008), bipolar disorder and dementia (Wischik et al.”
BackgroundMethodMoclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity
Isbister, G. K., Hackett, L. P., Dawson, A. H., Whyte, I. M., & Smith, A. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01895.x · Cited by 86 · cited 3×
“This is as predicted by the spectrum concept of ST, because even overdoses of selective reversible MAO-A inhibitors (RIMAs) do not precipitate ST (see Figure 3), as exemplified moclobemide (Isbister et al., 2003).”
BackgroundA controlled trial of methylene blue in severe depressive illness
Naylor, G. J., Smith, A. H. W., & Connelly, P. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90194-6 · Cited by 75 · cited 2×
“…potent selective reversible inhibitor of monoamine oxidase A (MAO-A) at nanomolar concentrations (Ramsay et al., 2007), confirming several older publications suggesting MB’s antidepressant activity and ability to raise serotonin (Aeschlimann et al., 1996; Naylor et al., 1987; Wegener et al., 2000).”
BackgroundAeschlimann, C., Cerny, T., & Kupfer, A. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08471-5 · Cited by 71 · cited 2×
“…potent selective reversible inhibitor of monoamine oxidase A (MAO-A) at nanomolar concentrations (Ramsay et al., 2007), confirming several older publications suggesting MB’s antidepressant activity and ability to raise serotonin (Aeschlimann et al., 1996; Naylor et al., 1987; Wegener et al., 2000).”
BackgroundNeurological sequelae following methylene blue injection for parathyroidectomy
Martindale, S. J., & Stedeford, J. C. (2003) · Anaesthesia · doi:10.1046/j.1365-2044.2003.03415_23.x · Cited by 67
Gillman, P. K. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.750 · Cited by 66 · cited 14×
“…spectrum concept of ST, which highlights that it is a synaptic 5-HT concentration related phenomenon; this spectrum concept has been elaborated, combining animal and human data, to show the extent to which various classes of drugs, and their various combinations, elevate serotonin (Gillman, 2006a).”
BackgroundMethodResultSelf-citationStanford, S. C., Stanford, B. J., & Gillman, P. K. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105450 · Cited by 66 · cited 7×
“Recent reviews of the pharmacology of MB discuss the evidence in relation to ST (Stanford et al., 2009) and other aspects of its pharmacology (Oz et al., 2009), including inhibition of inducible and constitutive nitric oxide synthase and the formation of L-citrulline.”
BackgroundMethodInfluentialSelf-citationBiswas, P. N., Wilton, L. V., & Shakir, S. A. W. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017001716 · Cited by 60 · cited 2×
“A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone, nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 20…”
BackgroundMethylene-Blue–Associated Encephalopathy
Sweet, G., & Standiford, S. B. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.030 · Cited by 59 · cited 1×
“Surgical retrospective case series There are two retrospective case series from units where MB was always used for parathyroid surgery that have reported on ‘CNS toxicity’: Kartha (Kartha et al., 2006) and Sweet (Sweet and Standiford, 2007).”
BackgroundParathyroid surgery and methylene blue: A review with guidelines for safe intraoperative use
Pollack, G., Pollack, A. Z., Delfiner, J., & Fernandez, J. (2009) · The Laryngoscope · doi:10.1002/lary.20581 · Cited by 55 · cited 2×
“…Majithia and Stearns (2006); (5) Mathew et al. (2006); (6) Rosenbaum (2006); (7) Khan et al. (2007); (8) Mihai et al. (2007); (9) Ng et al. (2008); (10) Shanmugam et al. (2008); (11) Khavandi et al. (2008); (12) Schwiebert et al. (2009); (13) Rowley et al. (2009); and (14) Pollack et al. (2009).”
BackgroundNg, B., Cameron, A. J. D., Liang, R., & Rahman, H. U. (2008) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03017595 · Cited by 51 · cited 2×
“…et al. (2004); (4) Majithia and Stearns (2006); (5) Mathew et al. (2006); (6) Rosenbaum (2006); (7) Khan et al. (2007); (8) Mihai et al. (2007); (9) Ng et al. (2008); (10) Shanmugam et al. (2008); (11) Khavandi et al. (2008); (12) Schwiebert et al. (2009); (13) Rowley et al. (2009); and (14)…”
BackgroundWaring, W. S., Good, A. M., & Bateman, D. N. (2007) · Clinical Toxicology · doi:10.1080/15563650601005837 · Cited by 49 · cited 2×
“A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone, nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 20…”
BackgroundStanford, B. J., & Stanford, S. C. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300322 · Cited by 40
Extracting value from case reports: lessons from serotonin toxicity
Gillman, P. K. (2006) · Anaesthesia · doi:10.1111/j.1365-2044.2006.04588.x · Cited by 30 · cited 14×
“…spectrum concept of ST, which highlights that it is a synaptic 5-HT concentration related phenomenon; this spectrum concept has been elaborated, combining animal and human data, to show the extent to which various classes of drugs, and their various combinations, elevate serotonin (Gillman, 2006a).”
BackgroundMethodResultInfluentialSelf-citationSerotonin syndrome following cardiac surgery
SHANMUGAM, G., Kent, B., Alsaiwadi, T., & Baskett, R. J. F. (2008) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1510/icvts.2007.173104 · Cited by 30 · cited 4×
“…Majithia and Stearns (2006); (5) Mathew et al. (2006); (6) Rosenbaum (2006); (7) Khan et al. (2007); (8) Mihai et al. (2007); (9) Ng et al. (2008); (10) Shanmugam et al. (2008); (11) Khavandi et al. (2008); (12) Schwiebert et al. (2009); (13) Rowley et al. (2009); and (14) Pollack et al. (2009).”
InfluentialMethylene Blue-Associated Serotonin Syndrome: A ‘Green’ Encephalopathy After Parathyroidectomy
Rowley, M., Riutort, K. T., Shapiro, D., Casler, J. D., Festić, E., & Freeman, W. D. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9206-z · Cited by 29 · cited 4×
“…Majithia and Stearns (2006); (5) Mathew et al. (2006); (6) Rosenbaum (2006); (7) Khan et al. (2007); (8) Mihai et al. (2007); (9) Ng et al. (2008); (10) Shanmugam et al. (2008); (11) Khavandi et al. (2008); (12) Schwiebert et al. (2009); (13) Rowley et al. (2009); and (14) Pollack et al. (2009).”
BackgroundInfluentialSmall doses of methylene blue, previously considered safe, can precipitate serotonin toxicity
Schwiebert, C., Irving, C., & Gillman, P. K. (2009) · Anaesthesia · doi:10.1111/j.1365-2044.2009.06029.x · Cited by 26
Self-citationOutcomes after Isolated Mirtazapine (Remeron™) Supratherapeutic Ingestions
LoVecchio, F., Riley, B. D., Pizon, A. F., & Brown, M. E. (2007) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2007.03.006 · Cited by 25 · cited 2×
“A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone, nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 20…”
BackgroundSerotonin toxicity precipitated by concomitant use of citalopram and methylene blue
Khavandi, A., Whitaker, J., & Gonna, H. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb02168.x · Cited by 21 · cited 3×
“…Majithia and Stearns (2006); (5) Mathew et al. (2006); (6) Rosenbaum (2006); (7) Khan et al. (2007); (8) Mihai et al. (2007); (9) Ng et al. (2008); (10) Shanmugam et al. (2008); (11) Khavandi et al. (2008); (12) Schwiebert et al. (2009); (13) Rowley et al. (2009); and (14) Pollack et al. (2009).”
BackgroundInfluentialUnderstanding Toxidromes: Serotonin Toxicity
Gillman, P. K. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186741.30019.a3 · Cited by 14 · cited 4×
“…diagnosis of NMS may be made because prior ingestion of an anti-psychotic is thought to ‘trump’ a diagnosis of ST: prior administration of anti-psychotics is not a reason to suspend a diagnosis of ST, if serotonergic drugs have been ingested and characteristic symptoms are present (Gillman, 2005b).”
BackgroundSelf-citationNefazodone Poisoning: Toxicokinetics and Toxicodynamics Using Continuous Data Collection
Isbister, G. K., & Hackett, L. P. (2003) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120019133 · Cited by 13 · cited 2×
“A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone, nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 20…”
BackgroundMirtazapine: Unable to Induce Serotonin Toxicity?
Gillman, P. K. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200311000-00003 · Cited by 10 · cited 2×
“A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone, nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 20…”
BackgroundSelf-citation
Cited by
Intelligent Food Packaging: A Review of Smart Sensing Technologies for Monitoring Food Quality
Yousefi, H., Su, H.-M., Imani, S. M., Alkhaldi, K., M. Filipe, C. D., & Didar, T. F. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00440 · Cited by 682
Recent advances in polymers and polymer composites for food packaging
Zhang, M., Biesold, G. M., Choi, W., Yu, J., Deng, Y., Silvestre, C., & Lin, Z. (2022) · Materials Today · doi:10.1016/j.mattod.2022.01.022 · Cited by 335
Luo, X., Zaitoon, A., & Lim, L. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12942 · Cited by 294
Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
Scotton, W. J., Hill, L. J., Williams, A. C., & Barnes, N. M. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919873925 · Cited by 267
Gillman, P. K. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1932-y · Cited by 255
Self-citation
Metadata
- Authors
- Gillman, P. K.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2010-02-08
- Volume
- 25
- Issue
- 3
- Pages
- 429-436
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2170622299
- Cited by
- 182
- References
- 39
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.